229 related articles for article (PubMed ID: 24194854)
1. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype.
Kim H; Jang SJ; Chung DH; Yoo SB; Sun P; Jin Y; Nam KH; Paik JH; Chung JH
PLoS One; 2013; 8(10):e76999. PubMed ID: 24194854
[TBL] [Abstract][Full Text] [Related]
2. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.
Possidente L; Landriscina M; Patitucci G; Borgia L; Lalinga V; Vita G
Med Oncol; 2017 May; 34(5):76. PubMed ID: 28364271
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
4. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
5. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features of lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements].
Dong Y; Zhou L; Wang J; Cai Y; Mu J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):436-40. PubMed ID: 26463147
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
Yoshida A; Tsuta K; Nakamura H; Kohno T; Takahashi F; Asamura H; Sekine I; Fukayama M; Shibata T; Furuta K; Tsuda H
Am J Surg Pathol; 2011 Aug; 35(8):1226-34. PubMed ID: 21753699
[TBL] [Abstract][Full Text] [Related]
8. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
9. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
Woo JH; Kim TJ; Kim TS; Han J
Sci Rep; 2020 Oct; 10(1):16251. PubMed ID: 33005033
[TBL] [Abstract][Full Text] [Related]
10. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.
Nishino M; Klepeis VE; Yeap BY; Bergethon K; Morales-Oyarvide V; Dias-Santagata D; Yagi Y; Mark EJ; Iafrate AJ; Mino-Kenudson M
Mod Pathol; 2012 Nov; 25(11):1462-72. PubMed ID: 22743652
[TBL] [Abstract][Full Text] [Related]
11. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Rodig SJ; Mino-Kenudson M; Dacic S; Yeap BY; Shaw A; Barletta JA; Stubbs H; Law K; Lindeman N; Mark E; Janne PA; Lynch T; Johnson BE; Iafrate AJ; Chirieac LR
Clin Cancer Res; 2009 Aug; 15(16):5216-23. PubMed ID: 19671850
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
[TBL] [Abstract][Full Text] [Related]
15. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
18. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
19. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.
Voena C; Varesio LM; Zhang L; Menotti M; Poggio T; Panizza E; Wang Q; Minero VG; Fagoonee S; Compagno M; Altruda F; Monti S; Chiarle R
Oncotarget; 2016 May; 7(22):33316-30. PubMed ID: 27119231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
